Evidence map›Paper›PMID 42104158›Full record

ArticleAnnals of hematology2026

WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy.

Hiroyuki Sugiura, Noboru Asada, Takeru Asano, Yasushi Hiramatsu, Tomohiro Urata, Toshi Imai, Makoto Nakamura, Kazuhiko Yamamoto, Tatsunori Ishikawa, Masanori Makita and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hiroyuki SugiuraDivision of Internal Medicine, Fukuyama City Hospital, Hiroshima, Japan.
Noboru AsadaDepartment of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. nasada@okayama-u.ac.jp.
Takeru AsanoDepartment of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
Yasushi HiramatsuDepartment of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
Tomohiro UrataDepartment of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
Toshi ImaiDepartment of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
Makoto NakamuraDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Kazuhiko YamamotoDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Tatsunori IshikawaDepartment of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan.
Masanori MakitaDepartment of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan.
Takanori YoshiokaDepartment of Hematology, NHO Okayama Medical Center, Okayama, Japan.
Kazutaka SunamiDepartment of Hematology, NHO Okayama Medical Center, Okayama, Japan.
Kyosuke SaekiDivision of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan.
Yuichiro NawaDivision of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan.
Maiko KimuraDepartment of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Makoto TakeuchiDepartment of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Masaya AbeDepartment of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Shoji AsakuraDepartment of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan.
Tomofumi YanoDepartment of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venetoclax and azacitidine (VEN/AZA), which target BCL-2 and DNA methylation, have demonstrated substantial efficacy, particularly in older or unfit patients with acute myeloid leukemia (AML). Wilms' Tumor-1 (WT1) mRNA, measurable in peripheral blood (PB), is an established biomarker for monitoring treatment response and predicting AML prognosis. We conducted a retrospective analysis of patients with AML treated with VEN/AZA within the Okayama Hematology Study Group (OHSG). Patients who showed a marked reduction in PB WT1 mRNA levels from baseline after the first or second treatment cycle had significantly improved overall survival (OS) and progression-free survival (PFS). Moreover, achieving PB WT1 mRNA negativity-regardless of whether this occurred early or later in the therapy།was consistently associated with superior OS and PFS. These findings suggest that PB WT1 mRNA is a sensitive and reliable biomarker for predicting treatment response and long-term outcomes in patients with AML receiving VEN/AZA.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBiomarkers, TumorLeukemia, Myeloid, AcuteRNA, MessengerRNA, NeoplasmWT1 ProteinsAgedAged, 80 and overBridged Bicyclo Compounds, HeterocyclicFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAzacitidineBiomarkers, TumorBridged Bicyclo Compounds, HeterocyclicRNA, MessengerRNA, NeoplasmSulfonamidesvenetoclaxWT1 protein, humanWT1 ProteinsAcute myeloid leukemiaAzacitidineMeasurable residual diseaseVenetoclaxWT1 mRNA

Identifiers

PMID42104158
PMCPMC13323449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.